Fierce Pharma
OCTOBER 29, 2024
Exactly three years after an initial FDA green light for the third-line treatment of leukemia, Novartis’ Scemblix has won an accelerated approval to treat newly diagnosed patients. | Exactly three years after an initial FDA green light for the third-line treatment of leukemia, Novartis’ Scemblix has won an accelerated approval to treat newly diagnosed patients.
MedCity News
OCTOBER 29, 2024
In this episode, we’re joined by Dr. Tiffany Inglis, national medical director for women and children’s health at Carelon Health, a subsidiary of Elevance Health. Inglis discusses a paper Elevance Health Public Policy Institute recently published about doulas. The post MedCity FemFwd: How Doulas Can Improve Maternal Health Outcomes appeared first on MedCity News.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Pharma
OCTOBER 29, 2024
Amid a looming standoff with activist investor Starboard Value, Pfizer fought back against accusations of underperforming by delivering double digit revenue growth over the third quarter and notchi | The company is projecting yearly sales of $61 billion to $64 billion in a $1.5 billion boost from previous forecasts.
MedCity News
OCTOBER 29, 2024
As companies begin to make plans for 2025, add the INVEST Pitch Perfect Contest to your calendar. The post Are You a Startup Looking for an Audience of Investors? We Have The Perfect Pitch Contest for You! appeared first on MedCity News.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Fierce Pharma
OCTOBER 29, 2024
As expected, Novartis’ radioligand therapy Pluvicto crossed the blockbuster sales threshold with one quarter still left of 2024. | Novartis didn't use a priority review voucher for Pluvicto's key application in an earlier treatment setting of prostate cancer. The company made the decision in response to the FDA's request for "flexibility" in its review timeline, Novartis CEO Vas Narasimhan explained.
pharmaphorum
OCTOBER 29, 2024
Patients in England and Wales with multiple myeloma are celebrating a decision by NICE to relax strict restrictions on eligibility to receive Pfizer's Elrexfio.In June, the cost-effectiveness agency cleared the use of the BCMAxCD3 bispecific antibody with 'optimised guidance' that allowed it to be used for a narrower range of patients than was covered by the approved label for the drug.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
MedCity News
OCTOBER 29, 2024
We know from everyday purchasing of goods and services that you have to combine what you’re getting with what you’re paying for that good or service. But how does this basic consumer supplier concept play out in US healthcare? The post VBC, MA, FHIR and Modern Care appeared first on MedCity News.
Fierce Pharma
OCTOBER 29, 2024
The FDA has approved the first abuse-deterrent, immediate-release, 10 mg opioid tablet for pain management. The drug, Roxybond, has been approved in other dosages.
MedCity News
OCTOBER 29, 2024
Crescent Biopharma is going public via a reverse merger with GlycoMimetics that will capitalize the combined company with $200 million. Crescent’s lead program is a bispecific antibody for cancer that replicates the properties of a Summit Therapeutics bispecific drug that recently trounced Merck’s blockbuster med Keytruda in a pivotal head-to-head study.
Fierce Pharma
OCTOBER 29, 2024
After the recent FDA approval for the promising schizophrenia drug Cobenfy (xanomeline and trospium chloride), Bristol Myers Squibb and its partners are moving fast to expand the global reach of th | In a phase 3 bridging study run by Zai Lab in China, Bristol Myers Squibb's KarXT helped schizophrenia patients chart a 9.2-point total-score reduction on the Positive and Negative Syndrome Scale versus placebo at week 5, teeing up a forthcoming regulatory filing.
Advertisement
Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.
pharmaphorum
OCTOBER 29, 2024
AbbVie agrees a $1.4bn cash deal to acquire Aliada Therapeutics, adding another anti-amyloid antibody to its Alzheimer's pipeline.
Fierce Pharma
OCTOBER 29, 2024
Incyte’s blockbuster JAK inhibitor Jakafi has been driving the company’s sales for years now, with this quarter being no different. | Meanwhile, the company also scrapped plans to expand its topical JAK Opzelura into two other skin disorders.
pharmaphorum
OCTOBER 29, 2024
An evaluation of digital health technologies for hypertension by the Peterson Health Technology Institute (PHTI) finds some provide a clinical benefit, while others are lacking.On the plus side, the health technology assessment (HTA) body has concluded that tools to help people manage their antihypertensive drug treatment can deliver benefits in reduced blood pressure.
MedCity News
OCTOBER 29, 2024
Large language models will soon become a much bigger part of doctors’ clinical workflows, former FDA Commissioner Scott Gottlieb said Tuesday at the 3rd Annual Summit on the Future of Rural Health Care. The post ‘You Almost Have to Be Doing It’: Why Scott Gottlieb Thinks All Doctors Will Use LLMs Soon appeared first on MedCity News.
pharmaphorum
OCTOBER 29, 2024
UK government confirms £1.8bn funding boost to NHS to cut waiting lists, including £1.
MedCity News
OCTOBER 29, 2024
Try a variety of LLM-based tools yourself. Understand the risks, limitations, and who is working on putting quality frameworks and guardrails in place. Engage your employees and partners in discussions about what might now be possible. The post A CEO’s Guide to AI Exploration: Transforming Organizations and Mindsets appeared first on MedCity News.
Impetus Digital
OCTOBER 29, 2024
Pharma-exclusive Webinar: Next-gen Virtual Tools for Education & Learning in the Life Sciences About the webinar Join us for one of three webinar sessions, tailored exclusively for Pharma leaders. Between November 18–20, we will delve into the future of educational tools in the life sciences industry. Our expert speakers will unveil the latest virtual tools that are reshaping how professionals engage with and educate HCPs, patients, and internal teams.
PharmaTech
OCTOBER 29, 2024
WHO and its partners are providing support to countries dealing with mpox outbreaks.
Advertisement
Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A
pharmaphorum
OCTOBER 29, 2024
The lengthening list of pharma alliances focused on molecular glue degraders has another entry after Novartis signed a deal with Monte Rosa Therapeutics worth up to $2.2 billion. The partnership – which has seen a $150 million upfront payment from Novartis alongside a pledge for up to $2.1 billion in milestones – gives the Swiss pharma group rights to Monte Rosa's VAV1-directed molecular glue degrader programme.
MedTechVets
OCTOBER 29, 2024
OCT 29TH: From October 15th-17th, the MedTechVets team had an incredible experience at The MedTech Conference in Toronto, Canada. This event brought together key players from across the medtech industry, fostering collaboration and innovation, while also emphasizing the importance of diversity and inclusion. Throughout the conference, MedTechVets advocated for veterans in the workforce, built meaningful connections, and hosted our highly anticipated second annual breakfast panel, “Building
pharmaphorum
OCTOBER 29, 2024
Pfizer CEO Albert Bourla hit back at activist investor Starboard Value, saying measures to reset the pharma group are already well in hand
European Pharmaceutical Review
OCTOBER 29, 2024
AbbVie has signed to acquire the biotech Aliada Therapeutics for $1.4 billion. The deal enables the advancement of a potentially best-in-class disease-modifying therapy for Alzheimer’s. Dr Roopal Thakkar , Executive Vice President, Research and Development and Chief Scientific Officer, AbbVie, highlighted that neuroscience is one of AbbVie’s key growth areas.
PharmaVoice
OCTOBER 29, 2024
As AstraZeneca builds up indications for Fasenra, an ongoing trial will determine whether the respiratory drug can make up for past stumbles in COPD.
Pharma Marketing Network
OCTOBER 29, 2024
Pharma advertising isn’t just about promoting products—it’s about reaching patients, caregivers, and healthcare professionals with valuable, meaningful information. With digital channels, evolving regulations, and changing patient expectations, creating an impactful advertising strategy can feel complex. In this article, we’ll explore key pharma advertising strategies that resonate with your audience, enhance brand engagement, and help you stay ahead in a competitive industry.
PharmaTech
OCTOBER 29, 2024
Marianna Tcherpakov, PhD, director of Business Development, CMC Services, at Frontage Laboratories, spoke on the CDMO’s role in tackling complex technical challenges to enable startup biotechs solve scale up problems.
PharmExec
OCTOBER 29, 2024
Roxybond is the and only FDA-approved abuse-deterrent immediate-release 10 mg oxycodone formulation designed to reduce abuse of pain medication via intranasal and intravenous routes.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
PharmaTech
OCTOBER 29, 2024
The collaboration aims to advance clinical development of a Phase I drug candidate, MRT-6160, and to explore other therapeutic opportunities across multiple indications.
PharmExec
OCTOBER 29, 2024
Scott Brunner, CEO, and Tenille Davis, Chief Advocacy Officer, of the Alliance for Pharmacy Compounding explore the potential long-term implications of the ongoing drug shortages for the healthcare system and patient care.
Pharmaceutical Technology
OCTOBER 29, 2024
The registrational trial is expected to support the approval for Bavarian’s mpox/smallpox vaccine use in children 2-11 years of age.
PharmExec
OCTOBER 29, 2024
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Expert insights. Personalized for you.
300 
Let's personalize your content